Correction to Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition [Hepatology, 62, (2015) 1201-1214], DOI: 10.1002/hep.27911;Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition

Hepatology

Volumn 62, Issue 4, 2015, Pages 1201-1214

  Wang, Zhi Chao ^a   Gao, Qiang ^a   Shi, Jie Yi ^a   Guo, Wei Jie ^a   Yang, Liu Xiao ^a   Liu, Xin Yang ^b   Liu, Long Zi ^a   Ma, Li Jie ^a   Duan, Meng ^a   Zhao, Ying Jun ^b   Wu, Yong Na ^c   Gao, Dong Mei ^a   Wang, Xiao Ying ^a   Shi, Guo Ming ^a   Ding, Zhen Bin ^a   Ke, Ai Wu ^a   Tang, Qi Qun ^d   Cao, Ya ^e   Zhou, Jian ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c LANZHOU UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR S; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; GROWTH FACTOR RECEPTOR; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR INVASION; TUMOR VOLUME; LIVER TUMOR; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL CULTURE;

CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; RECEPTORS, GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 84942553117     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28350     Document Type: Erratum

References (35)

1. Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015;61:191-199.
2. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014;20:2072-2079.
5. Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2011;11:35-49.
6. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006;6:307-320.
7. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187.
8. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006;7:833-846.
9. Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, et al. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology 2014;59:190-201.
10. Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, et al. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology 2013;57:678-688.
11. Bera R, Chiou CY, Yu MC, Peng JM, He CR, Hsu CY, et al. Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis. Hepatology 2014;59:2238-2250.
12. Wagner J, Gordon LA, Heng HH, Tremblay ML, Olsen AS. Physical mapping of receptor type protein tyrosine phosphatase sigma (PTPRS) to human chromosome 19p13.3. Genomics 1996;38:76-78.
13. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein tyrosine phosphatases in the human genome. Cell 2004;117:699-711.
14. Meathrel K, Adamek T, Batt J, Rotin D, Doering LC. Protein tyrosine phosphatase sigma-deficient mice show aberrant cytoarchitecture and structural abnormalities in the central nervous system. J Neurosci Res 2002;70:24-35.
15. Rashid-Doubell F, McKinnell I, Aricescu AR, Sajnani G, Stoker A. Chick PTPsigma regulates the targeting of retinal axons within the optic tectum. J Neurosci 2002;22:5024-5033.
16. Shen Y, Tenney AP, Busch SA, Horn KP, Cuascut FX, Liu K, et al. PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science 2009;326:592-596.
17. Muise AM, Walters T, Wine E, Griffiths AM, Turner D, Duerr RH, et al. Protein-tyrosine phosphatase sigma is associated with ulcerative colitis. Curr Biol 2007;17:1212-1218.
18. Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A 2011;108:19024-19029.
19. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113.
20. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 2008;68:10300-10306.
21. Gao Q, Zhao YJ, Wang XY, Guo WJ, Gao S, Wei L, et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 2014;146:1397-1407.
22. Zhou ZJ, Dai Z, Zhou SL, Hu ZQ, Chen Q, Zhao YM, et al. HNRNPAB induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL. Cancer Res 2014;74:2750-2762.
23. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004;130:460-468.
24. Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res 2012;72:3546-3556.
25. Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology 2012;143:1641-1649.e5.
26. Motiwala T, Datta J, Kutay H, Roy S, Jacob ST. Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib. J Cell Biochem 2010;110:846-856.
27. Blanchetot C, Chagnon M, Dube N, Halle M, Tremblay ML. Substrate-trapping techniques in the identification of cellular PTP targets. Methods 2005;35:44-53.
28. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-345.
29. Friemel J, Rechsteiner MP, Frick L, Boehm F, Struckmann K, Sigg M, et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res 2015;21:1951-1961.
30. Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol 2000;2:E231-E236.
31. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, et al. Signatures of mutation and selection in the cancer genome. Nature 2010;463:893-898.
32. Siu R, Fladd C, Rotin D. N-cadherin is an in vivo substrate for protein tyrosine phosphatase sigma (PTPsigma) and participates in PTPsigma-mediated inhibition of axon growth. Mol Cell Biol 2007;27:208-219.
33. Murchie R, Guo CH, Persaud A, Muise A, Rotin D. Protein tyrosine phosphatase sigma targets apical junction complex proteins in the intestine and regulates epithelial permeability. Proc Natl Acad Sci U S A 2014;111:693-698.
34. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-D950.
35. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010;70:27-56.